[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BRPI1015941A2 - formulações de comprimido de 3-cianoquinolina e uso das mesmas. - Google Patents

formulações de comprimido de 3-cianoquinolina e uso das mesmas.

Info

Publication number
BRPI1015941A2
BRPI1015941A2 BRPI1015941A BRPI1015941A BRPI1015941A2 BR PI1015941 A2 BRPI1015941 A2 BR PI1015941A2 BR PI1015941 A BRPI1015941 A BR PI1015941A BR PI1015941 A BRPI1015941 A BR PI1015941A BR PI1015941 A2 BRPI1015941 A2 BR PI1015941A2
Authority
BR
Brazil
Prior art keywords
cyanoquinoline
tablet formulations
formulations
tablet
cyanoquinoline tablet
Prior art date
Application number
BRPI1015941A
Other languages
English (en)
Portuguese (pt)
Inventor
Arwinder Nagi
Goldi Kaul
Krishnendu Ghosh
Ramarao Chatlapalli
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of BRPI1015941A2 publication Critical patent/BRPI1015941A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2031Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
BRPI1015941A 2009-07-02 2010-06-30 formulações de comprimido de 3-cianoquinolina e uso das mesmas. BRPI1015941A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22253709P 2009-07-02 2009-07-02
PCT/US2010/040555 WO2011002857A2 (en) 2009-07-02 2010-06-30 3-cyanoquinoline tablet formulations and uses thereof

Publications (1)

Publication Number Publication Date
BRPI1015941A2 true BRPI1015941A2 (pt) 2016-04-19

Family

ID=42732381

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1015941A BRPI1015941A2 (pt) 2009-07-02 2010-06-30 formulações de comprimido de 3-cianoquinolina e uso das mesmas.

Country Status (15)

Country Link
EP (1) EP2448563A2 (es)
JP (1) JP2011012063A (es)
KR (1) KR20120046216A (es)
CN (1) CN102470109A (es)
AR (1) AR077546A1 (es)
AU (1) AU2010266342A1 (es)
BR (1) BRPI1015941A2 (es)
CA (1) CA2766067A1 (es)
IL (1) IL217298A0 (es)
MX (1) MX2012000048A (es)
RU (1) RU2011152105A (es)
SG (1) SG177309A1 (es)
TW (1) TW201113050A (es)
WO (1) WO2011002857A2 (es)
ZA (1) ZA201200366B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1848414T3 (pl) 2005-02-03 2011-10-31 Wyeth Llc Sposób leczenia nowotworu opornego na gefitinib
EP1942937A1 (en) 2005-11-04 2008-07-16 Wyeth Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
ES2609232T3 (es) 2008-06-17 2017-04-19 Wyeth Llc Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina
EP3175853B1 (en) 2008-08-04 2023-11-01 Wyeth LLC Antineoplastic combinations of neratinib and capecitabine
FI3000467T3 (fi) 2009-04-06 2023-03-28 Wyeth Llc Rintasyöpähoitokuuri, jossa käytetään neratinibia
CN107308130B (zh) 2009-11-09 2021-06-15 惠氏有限责任公司 包衣药物球状体及消除或减少病症如呕吐和腹泻的用途
NZ599763A (en) * 2009-11-09 2014-06-27 Wyeth Llc Tablet formulations of neratinib maleate
CN104447541A (zh) * 2013-09-16 2015-03-25 天津市汉康医药生物技术有限公司 博舒替尼化合物
CN105384686B (zh) * 2014-09-04 2019-07-26 连云港润众制药有限公司 一种博舒替尼结晶方法
WO2017175855A1 (en) * 2016-04-08 2017-10-12 Shionogi & Co., Ltd. Stabilized solid dosage form
JP7086938B2 (ja) 2017-03-31 2022-06-20 日精エー・エス・ビー機械株式会社 樹脂製容器

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6297258B1 (en) 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
AU2003208444B2 (en) * 2002-02-26 2006-10-26 Astrazeneca Ab Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative
BRPI0413667A (pt) 2003-08-19 2006-10-24 Wyeth Corp Processo para a preparação de 4-amino-3-carbonitrilas de quinolina
US8969379B2 (en) * 2004-09-17 2015-03-03 Eisai R&D Management Co., Ltd. Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7=methoxy-6-quinolinecarboxide
KR20080028386A (ko) * 2005-07-01 2008-03-31 와이어쓰 4-[(2,4-디클로로-5-메톡시페닐)아미노]-6-메톡시-7-[3-(4-메틸-1-피페라지닐)프로폭시]-3-퀴놀린카르보니트릴의결정형 형태 및 그의 제조 방법
WO2008053295A2 (en) * 2006-10-30 2008-05-08 Wockhardt Research Centre Pharmaceutical compositions of benzoquinolizine-2-carboxylic acid
CN101224185A (zh) * 2007-12-11 2008-07-23 山东蓝金生物工程有限公司 一种治疗实体肿瘤的伯舒替尼缓释植入剂

Also Published As

Publication number Publication date
CN102470109A (zh) 2012-05-23
JP2011012063A (ja) 2011-01-20
SG177309A1 (en) 2012-02-28
EP2448563A2 (en) 2012-05-09
IL217298A0 (en) 2012-02-29
CA2766067A1 (en) 2011-01-06
AU2010266342A1 (en) 2012-01-19
RU2011152105A (ru) 2013-08-10
ZA201200366B (en) 2012-10-31
KR20120046216A (ko) 2012-05-09
TW201113050A (en) 2011-04-16
WO2011002857A3 (en) 2011-03-10
MX2012000048A (es) 2012-01-27
AR077546A1 (es) 2011-09-07
WO2011002857A2 (en) 2011-01-06

Similar Documents

Publication Publication Date Title
LTPA2020003I1 (lt) Dvisluoksnės tabletės formuluotės
BRPI1015941A2 (pt) formulações de comprimido de 3-cianoquinolina e uso das mesmas.
BRPI1008709A2 (pt) composições e usos das mesmas.
BR112012013148A2 (pt) formulação farmacêutica e uso
BR112012005736A2 (pt) di-hidro benzocicloalquiloximetil oxazolapirimidinonas substituídas, preparação e uso das mesmas
BRPI1014160A2 (pt) Formulações de nanopartículas e aplicações das mesmas
BR112012011733A2 (pt) formulações de comprimido de liberação imediata
BRPI0911656A2 (pt) formulações de nanopartículas e usos das mesmas
BR112012003792A2 (pt) gel tópico, e, uso do gel tópico.
SMT201400069B (it) Formulazione farmaceutica
BRPI0820381A2 (pt) Formulações farmacêuticas
BRPI1016117A8 (pt) derivados de isoxazol-isoxazol e isoxazol-isotiazol.
BR112012004335A2 (pt) composto, composição farmacêutica, e, uso do composto.
IT1403847B1 (it) Composizioni farmaceutiche comprendenti rifaximina e loro uso.
BR112012031226A2 (pt) composto, uso do composto, composição farmacêutica, e uso de composição farmacêutica
GT201200303A (es) Formulaciones farmacéuticas
BR112012003800A2 (pt) composição, peptídeo, e formulação farmacêutica.
BR112012003844A2 (pt) vacinas de pttv e diagnóstico
BRPI1014388A2 (pt) preparação de sólido.
BRPI1014898A2 (pt) cosmético capilar.
BRPI0915527A2 (pt) pepitídeos, composição farmacêutica e exossomos compreendendo os mesmos, métodos e usos
BR112012002311A2 (pt) composto, composição farmacêutica, e, uso do composto.
BRPI0907700A2 (pt) Imidazopiridazinas como inibidores par1, produção das mesmas e uso como medicamentos
BR112012014495A2 (pt) cosmético de autonivelamento.
BR112012002293A2 (pt) composto, composição farmacêutica, e, uso do composto

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]